Nanobiotix announced the presentation of first data from the Johnson & Johnson-sponsored Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3) in stage 3 inoperable non-small cell lung cancer, showing an acceptable safety profile and promising initial efficacy responses.
Key takeaways
First data from the randomized Phase 2 CONVERGE study evaluating JNJ-1900 (NBTXR3) for stage 3 inoperable non-small cell lung cancer was presented at the 2026 European Lung Cancer Conference.
The study demonstrated an acceptable safety profile without serious treatment-emergent adverse events and did not adversely impact patients' ability to continue planned therapy.
Initial efficacy responses observed in 7 patients at first disease evaluation showed an objective response rate of 71.4% and a disease control rate of 100%, relative to an estimated benchmark of 45%-50%.
JNJ-1900 (NBTXR3) is a novel, potentially first-in-class oncology product composed of functionalized hafnium oxide nanoparticles administered via one-time intratumoral injection and activated by radiotherapy.
Nanobiotix entered into a license agreement for the global co-development and commercialization of JNJ-1900 (NBTXR3) with Janssen Pharmaceutica NV, a Johnson & Johnson company, in 2023.